iRadimed (FRA:46K) Cyclically Adjusted FCF per Share: €0.75 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:46K iRadimed Corp FRA:46K
88 GF Score
Price €84.50
GF Value €56.35
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is iRadimed Cyclically Adjusted FCF per Share?

iRadimed FRA:46K +4.97% 88 Cyclically Adjusted FCF per Share is €0.75 as of Mar. 2026. GuruFocus rates FRA:46K with a GF Score™ of 88/100 and a GF Value™ of €56.35 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

iRadimed's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.526. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.75 for the trailing ten years ended in Mar. 2026.

During the past 12 months, iRadimed's average Cyclically Adjusted FCF Growth Rate was 15.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of iRadimed was 12.20% per year. The lowest was 12.20% per year. And the median was 12.20% per year.

As of today (2026-07-19), iRadimed's current stock price is €84.50. iRadimed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €0.75. iRadimed's Cyclically Adjusted Price-to-FCF of today is 112.67.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of iRadimed was 126.29. The lowest was 47.90. And the median was 72.43.


iRadimed  (FRA:46K) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

iRadimed's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=84.50/0.75
=112.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of iRadimed was 126.29. The lowest was 47.90. And the median was 72.43.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


iRadimed Cyclically Adjusted FCF per Share Related Terms


iRadimed Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for iRadimed's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iRadimed Cyclically Adjusted FCF per Share Chart

iRadimed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.55 0.55 0.70 0.70

iRadimed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.67 0.67 0.70 0.75

FRA:46K vs AVNS, LMRI, AORT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, iRadimed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRadimed Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where iRadimed's Cyclically Adjusted Price-to-FCF falls into.


FRA:46K
88GF Score
iRadimed Corp FRA:46K
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iRadimed Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, iRadimed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.526/330.2130*330.2130
=0.526

Current CPI (Mar. 2026) = 330.2130.

iRadimed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.062 241.018 0.085
201609 0.246 241.428 0.336
201612 0.147 241.432 0.201
201703 -0.037 243.801 -0.050
201706 0.009 244.955 0.012
201709 0.119 246.819 0.159
201712 0.090 246.524 0.121
201803 0.106 249.554 0.140
201806 0.103 251.989 0.135
201809 0.047 252.439 0.061
201812 0.247 251.233 0.325
201903 0.041 254.202 0.053
201906 0.175 256.143 0.226
201909 0.224 256.759 0.288
201912 0.271 256.974 0.348
202003 0.071 258.115 0.091
202006 0.044 257.797 0.056
202009 0.083 260.280 0.105
202012 0.157 260.474 0.199
202103 0.052 264.877 0.065
202106 0.225 271.696 0.273
202109 0.213 274.310 0.256
202112 0.223 278.802 0.264
202203 0.072 287.504 0.083
202206 0.091 296.311 0.101
202209 0.270 296.808 0.300
202212 0.192 296.797 0.214
202303 -0.141 301.836 -0.154
202306 0.227 305.109 0.246
202309 0.070 307.789 0.075
202312 0.236 306.746 0.254
202403 0.246 312.332 0.260
202406 0.391 314.175 0.411
202409 0.360 315.301 0.377
202412 0.218 315.605 0.228
202503 0.027 319.799 0.028
202506 0.333 322.561 0.341
202509 0.379 324.800 0.385
202512 0.365 324.054 0.372
202603 0.526 330.213 0.526

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.75 mean?
iRadimed (FRA:46K) has a Cyclically Adjusted FCF per Share of €0.75 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on iRadimed and its competitors.
Is iRadimed's Cyclically Adjusted FCF per Share too high?
iRadimed's current Cyclically Adjusted FCF per Share is €0.75. Overall, iRadimed has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's Cyclically Adjusted FCF per Share compare to AVNS and LMRI?
iRadimed's Cyclically Adjusted FCF per Share of €0.75 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on iRadimed and its competitors. iRadimed's current Cyclically Adjusted FCF per Share is €0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.35, compared to a current price of €84.50 — trading 50% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.75. iRadimed's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For iRadimed (FRA:46K), the current Cyclically Adjusted FCF per Share is €0.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iRadimed (FRA:46K) Overvalued in 2026?

Based on GuruFocus' analysis, iRadimed stock appears to be overvalued. The current stock price of €84.50 is trading 50% above its estimated GF Value™ of €56.35. GuruFocus considers iRadimed to be Significantly Overvalued.

Key valuation signals for FRA:46K:

  • Cyclically Adjusted FCF per Share: €0.75
  • GF Value™: €56.35 vs. price of €84.50 (50% above fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iRadimed Business Description

Other Exchanges IRMD:USA
Address 12705 Ingenuity Drive, Orlando, FL, USA, 32826
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
88GF Score

Get the complete analysis for FRA:46K

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€84.50
Price
€56.35
GF Value